When was Xspray founded?

Xspray was founded in 2003 and raised its 1st funding round 16 years after it was founded.

Where is Xspray located?

Xspray is headquartered in Solna, Sweden.

How many employees does Xspray have?

As of Aug 31, 2026, the latest employee count at Xspray is 33.

Is Xspray a funded company?

Xspray is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Dec 05, 2019.

When was the latest funding round of Xspray?

Xspray's latest funding was a $***** Post IPO round on Oct 23, 2020, with participation from 0 investor.

Where does Xspray rank among its competitors?

Xspray ranks 36th amongst 296 active competitors, of which 110 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Lyell Immunopharma, which secured $100M in Jul, 2025.

Who are the top competitors of Xspray?

Xspray's top competitors include Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics. Among them, Lyell Immunopharma secured the most recent funding round in July, 2025.

Xspray - 2026 Company Profile, Team, Funding & Competitors

Xspray is a public company based in Solna (Sweden), founded in 2003. It operates as a Developer of therapies for treating cancer. Xspray has raised an undisclosed amount in funding. The company has 296 active competitors, including 110 funded and 62 that have exited. Its top competitors include companies like Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics.

Company Details

Xspray is developing therapies for treating cancer. They are reformulating and developing protein kinase inhibitors for treating various cancers. They have developed a patented technology, RightSize, which is based on supercritical fluid extraction method.

Website: xspraypharma.com
Email ID: *****@xspraypharma.com
Phone Number: +46 **********

Key Metrics

Founded Year

2003

Location

Solna, Sweden

Stage

Public

Latest Funding Round

Post IPO, Oct 23, 2020, $*****

Investors

Fjarde AP-fonden & 7 more

Ranked

36^th among 296 active competitors

Employee Count

33 as on Aug 31, 2026

Similar Companies

Abcellera Biologics & 384 more

Exit Details

Public

View Xspray's full profile

Xspray got listed on Jan 19, 2018.

Click here to take a look at Xspray's IPO in detail

Xspray has raised funding over 2 rounds. Its first funding round was on Dec 05, 2019. Xspray has 8 institutional investors.

Here is the list of recent funding rounds of Xspray:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 23, 2020	5083147	Post IPO	1910431	3643122	8319509	6815954
Dec 05, 2019	7240670	Post IPO	6271299	1873916	9322040	C WorldWide Asset Management & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Xspray's funding rounds and investors

Xspray's employee count trend

Xspray has 33 employees as of Aug 26. Here is Xspray's employee count trend over the years:

Uncover Xspray's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Xspray include Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics. Here is the list of Top 10 competitors of Xspray, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
2nd	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
3rd	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	BlackRock, RA Capital Management & 9 others	70/100
4th	Beijing Jiakesi drug development 2015, Beijing (China), Public	Developer of small molecule based therapeutics for cancer treatment	$55M	Qiming Venture Partners, Lilly Asia Ventures ... & 3 others	66/100
5th	Boundless Bio 2018, San Diego (United States), Public	Developer of therapeutics for cancer by targeting ecDNA	$252M	RA Capital Management, Nextech Invest & 19 others	65/100
6th	Lyell Immunopharma 2018, San Francisco (United States), Public	Developer of CAR- T therapy for cancer treatment	$493M	Sahsen Ventures, GSK & 5 others	63/100
7th	ABL Bio 2016, Seongnam-si (South Korea), Public	Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases	$65M	QUAD, Hana Financial Group & 7 others	63/100
8th	Cumulus Oncology 2017, Edinburgh (United Kingdom), Seed	Developer of therapies for treating cancers	$19.2M	Eos Advisory, Scottish Investment Bank & 26 others	61/100
9th	Black Diamond Therapeutics 2017, Cambridge (United States), Public	Developing MasterKey therapies to defeat cancer resistance and improve patient lives	$207M	New Enterprise Associates, Boxer Capital ... & 19 others	61/100
10th	Bolt Biotherapeutics 2015, Redwood City (United States), Public	Developer of T-cell therapies for the treatment of cancer	$177M	Pivotal bioVenture Partners, Nan Fung Life Sciences ... & 7 others	61/100
36th	Xspray 2003, Solna (Sweden), Public	Developer of therapies for treating cancer	-	Fjarde AP-fonden, AP3 & 6 others	51/100